Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.05 USD
Change Today -0.03 / -0.97%
Volume 10.7K
BCLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 11:21 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Snapshot

Open
$3.08
Previous Close
$3.08
Day High
$3.10
Day Low
$3.04
52 Week High
01/2/15 - $8.47
52 Week Low
08/24/15 - $2.50
Market Cap
56.4M
Average Volume 10 Days
92.6K
EPS TTM
$-0.58
Shares Outstanding
18.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BRAINSTORM CELL THERAPEUTICS (BCLI)

brainstorm cell therapeutics (BCLI) Related Bloomberg News

View More Bloomberg News

brainstorm cell therapeutics (BCLI) Related Businessweek News

No Related Businessweek News Found

brainstorm cell therapeutics (BCLI) Details

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease. It holds the rights to develop and commercialize its NurOwn technology through licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is headquartered in Hackensack, New Jersey.

19 Employees
Last Reported Date: 08/13/15
Founded in 2000

brainstorm cell therapeutics (BCLI) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $154.0K
President
Total Annual Compensation: --
Chief Operating Officer and Director
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2014.

brainstorm cell therapeutics (BCLI) Key Developments

Brainstorm Cell Therapeutics Inc. Announces Amendments to its Articles of Incorporation

Brainstorm Cell Therapeutics Inc. at the AGM conducted on August 26, 2015 approved amendment to the company's certificate of incorporation to reduce the number of authorized shares of the company's common stock from 800,000,000 to 100,000,000.

Brainstorm Cell Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

BrainStorm Cell Therapeutics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported operating loss of $2,363,000 compared to $1,294,000 a year ago. Net loss was $2,265,000 or $0. 12 per basic and diluted share compared with $1,984,000 or $0.16 per basic and diluted share a year ago. Total net cash used in operating activities was $1,650,000 compared to $970,000 a year ago. Purchase of property and equipment was $16,000. For the six months, the company reported operating loss of $4,568,000 compared to $2,325,000 a year ago. Net loss was $4,501,000, or $0. 24 per basic and diluted share compared to $4,095,000 or $0.34 per basic and diluted share a year ago. Total net cash used in operating activities was $3,587,000 compared to $1,361,000 a year ago. Purchase of property and equipment was $16,000 compared to $94,000 a year ago.

Brainstorm Cell Therapeutics Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. announced that it has completed enrollment in its ongoing randomized, double-blind placebo-controlled phase 2 clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS). The targeted enrollment of 48 subjects has been achieved. This multi-center, randomized, double blind, placebo controlled study is evaluating the safety and efficacy of a single combined intramuscular and intrathecal administration of MSC-NTF cells (NurOwn®) in early-stage ALS patients. After enrolling in the study, subjects are followed for a three months run-in period, during which their bone-marrow is harvested and mesenchymal stromal cells are isolated and expanded. Subjects are then randomized to receive either NurOwn® or placebo, after which they are followed for six months.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $3.05 USD -0.03

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit www.brainstorm-cell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.